Elicio Therapeutics, Inc. (ELTX) stock
Close on Nov 12, 2026Market cap $41.00MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $41.00M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$35.74M
- EPS, diluted
- -$1.88
- Free cash flow
- -$36.97M
- Book value per share
- $0.72
- Diluted shares
- 26M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $1.63
- Open
- $1.59
- Day's range
- $1.55 – $1.65
- Volume
- 232,812
- Average volume (20 days)
- 332,075
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.53
- 52-week range
- $1.25 – $16.00
- RSI (14 days)
- 42.5
- Volatility (1 year)
- 143.9%
- Relative volume
- 0.60×
- WACC
- 12.5%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELTX | S&P 500 | Difference | ELTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.0% | -2.7% | −14.3 pts | ||
| 3 months | -49.0% | -1.7% | −47.3 pts | ||
| Year to date | -80.4% | +11.9% | −92.3 pts | ||
| 1 year | -83.0% | +12.0% | −95.0 pts | ||
| 3 years | -73.4% | +78.2% | −151.6 pts | -35.7% | +21.2% |
| 5 years | -96.5% | +73.2% | −169.7 pts | -48.8% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Elicio Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Update
- News
- News
About Elicio Therapeutics
Pharmaceutical Preparations
Elicio Therapeutics is a clinical-stage biotechnology company that develops novel cancer immunotherapies, specifically targeting oncogenic drivers such as mutant Kirsten rat sarcoma viral oncogene homolog (mKRAS) in pancreatic, colorectal, and lung cancers. The company utilizes its proprietary Amphiphile platform, which leverages albumin hitchhiking to deliver therapeutic payloads directly to lymph nodes to generate robust, cancer-specific T cell responses. Its clinical pipeline is led by ELI-002, an off-the-shelf lymph-node-targeted peptide immunotherapy evaluated in Phase 1 and Phase 2 trials for mKRAS-driven solid tumors. Its preclinical programs include ELI-007 and ELI-008, targeting mutant BRAF and TP53 driver mutations, respectively, alongside potential platform applications for cellular therapies and auto-immune conditions.
Company profile, executives and historyElicio Therapeutics stock: common questions
What is Elicio Therapeutics's stock price?
ELTX closed at $1.56 on Nov 12, 2026, down 4.29% on the day. Over the past 52 weeks it traded between $1.25 and $16.00.
What is Elicio Therapeutics's market cap?
Elicio Therapeutics was worth $41.00M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ELTX's P/E ratio?
Elicio Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.88), so it has no meaningful P/E ratio.
Does Elicio Therapeutics pay a dividend?
No. Elicio Therapeutics has not paid a cash dividend over the last twelve months.
When does Elicio Therapeutics report earnings next?
Elicio Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ELTX stock performed over the past year?
Including dividends, ELTX returned -83.0% over the past year, against +12.0% for the S&P 500.
How many ELTX shares are sold short?
2M shares were sold short at the latest FINRA report, 12.96% of the float, or 5.9 days of average trading volume.
Who are Elicio Therapeutics's competitors?
Companies most similar to Elicio Therapeutics by business, industry and size include MRKR, RNAZ, JANX, APVO, CTMX.
See a number that looks wrong?